INTERFERON ENHANCED INTRAPERITONEAL RADIOIMMUNITY FOR OVARIAN CANCER

干扰素增强卵巢癌腹腔内放射免疫

• 批准号: 6303038
• 负责人: ALBERT F LOBUGLIO
• 金额: $ 2.95万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6303038
• 关键词: clinical research; clinical trial phase I; combination cancer therapy; dosage; female; human subject; human therapy evaluation; interferons; monoclonal antibody; neoplasm /cancer radionuclide therapy; neoplasm /cancer relapse /recurrence; ovary neoplasms; paclitaxel; peritoneal cavity; radiosensitizer; women's health

Patients receive intraperitoneal Taxol and radiolabeled antibody. Therapy has generally been well tolerated with expected reversible marrow suppression among most patients. Taxol has added only minimally to the marrow suppression noted with radiolabeled antibody alone.

患者接受腹膜内泰素和放射性标记抗体。 在大多数患者中，治疗通常耐受性良好，预期可逆性骨髓抑制。 紫杉醇仅极轻微地增加了单独使用放射性标记抗体所观察到的骨髓抑制。